FETAL STEM CELLS FOR TRANSPLANTATION

用于移植的胎儿干细胞

• 批准号: 2205152
• 负责人: DAVID WARE BRANCH
• 金额: $ 23.92万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-08-01 至 1998-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2205152
• 关键词: Chlamydiaceae; Herpesviridae disease; bacterial disease; cell type; chromosome aberrations; cryopreservation; cytokine; hematopoietic stem cells; hematopoietic tissue transplantation; high performance liquid chromatography; human fetus tissue; human tissue; in situ hybridization; induced abortion; information systems; polymerase chain reaction; questionnaires; virus diseases

Transplantation of fetal tissues has been advocated as a means of treating various life-threatening conditions. Fetal cells may be uniquely suited for transplantation because of: (1) their ability to grow and proliferate, (2) their ability to undergo cell and tissue differentiation (intrinsic plasticity), (3) their ability to produce growth factors, and (4) their reduced antigenicity compared to adult cells. If properly and ethically obtained, induced abortions would seem a voluminous source of transplantable cells and tissues this country. However, induced abortion tissues, and the women who would donate the tissues, have not been exhaustively characterized to determine if they are suitable for transplantation purposes. In addition, the optimal methods for collecting, processing, evaluating, maintaining, and banking fetal tissues and cell lines has not been determined. Our group is primarily interested in the use of fetal hematopoietic stem cells for in utero transplantation to treat inborn errors of metabolism, immune deficiencies, and hematologic disorders. We propose to characterize induced abortion tissues and the women donating the tissues with regard to suitability for fetal tissue transplantation. We plan to use protocols previously developed for the study of spontaneous abortions and currently in use to characterize induced abortion specimens with respect to bacterial and viral contamination, morphological abnormalities, and cytogenetic abnormalities. We will test whether our use of DNA technology to search for infectious and genetic etiologies may be more efficient and perhaps more sensitive than traditional microbiologic and cytogenetic techniques. We also will determine the yield, growth potential, cell types, and immunologic characteristics of cultured hematopoietic stem cells. Finally we will also determine whether the cultured cells can be cryopreserved, transported, and transplanted in a well-established in utero transplantation model.

移植胎儿组织已被提倡作为一种治疗手段 各种危及生命的情况胎儿细胞可能是唯一适合 用于移植，因为：（1）它们生长和增殖的能力， (2)它们经历细胞和组织分化的能力（内在的 可塑性），（3）它们产生生长因子的能力，以及（4）它们的 与成人细胞相比，抗原性降低。如果在道德上 获得，人工流产似乎是一个巨大的来源， 可移植的细胞和组织然而，人工流产 组织，以及那些愿意捐赠组织的女性，还没有被 彻底表征，以确定它们是否适用于 移植的目的。此外，最佳的收集方法， 胎儿组织和细胞的处理、评估、保存和储存 线尚未确定。我们的团队主要对 胎儿造血干细胞在子宫内移植中的用途 治疗先天性代谢缺陷、免疫缺陷和血液病 紊乱我们建议对人工流产组织进行表征， 捐献组织的妇女是否适合胎儿组织 移植我们计划使用以前开发的协议 自然流产的研究，目前用于表征 人工流产标本中的细菌和病毒 污染、形态异常和细胞遗传学异常。 我们将测试我们是否使用DNA技术来寻找传染性 遗传病因学可能更有效，也更敏感 而不是传统的微生物和细胞遗传学技术。我们也将 确定产量、生长潜力、细胞类型和免疫学 造血干细胞的特征。最后，我们还将 确定培养的细胞是否可以冷冻保存，运输， 并移植到完善的子宫内移植模型中。